Caroline Mari Ramos Oda

Dr. Caroline Mari Ramos Oda

Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, UFMG, Belo Horizonte 31270-901, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Polymers
Verified
Journal Article
Open access
PDF file
FCFernanda Lapa Campos
Fernanda Lapa Campos
JLJanaina Alcantara Lemos
Janaina Alcantara Lemos
Caroline Mari Ramos OdaCaroline Mari Ramos Oda
Caroline Mari Ramos Oda
Juliana de Oliveira SilvaJuliana de Oliveira Silva
Juliana de Oliveira Silva
RFRenata Salgado Fernandes
Renata Salgado Fernandes
ABAndre Luis Branco de Barros
Andre Luis Branco de Barros
Colorectal cancer has been considered a worldwide public health problem since current treatments are often ineffective. Irinotecan is a frontline chemotherapeutic agent that has dose-limiting side effects that compromise its therapeutic potential. Therefore, it is necessary to develop a novel, targeted drug delivery system with high therapeutic efficacy and an improved safety profile. Here, micellar formulations composed of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-mPEG2k) containing irinotecan were proposed as a strategy for colorectal cancer therapy. Firstly, the irinotecan-loaded micelles were prepared using the solvent evaporation method. Then, micelles were characterized in terms of size, polydispersity, zeta potential, entrapment efficiency, and release kinetics. Cytotoxicity and in vivo antitumor activity were evaluated. The micelles showed size around 13 nm, zeta potential near neutral (−0.5 mV), and encapsulation efficiency around 68.5% (irinotecan 3 mg/mL) with a sustained drug release within the first 8 h. The micelles were evaluated in a CT26 tumor animal model showing inhibition of tumor growth (89%) higher than free drug (68.7%). Body weight variation, hemolytic activity, hematological, and biochemical data showed that, at the dose of 7.5 mg/kg, the irinotecan-loaded micelles have low toxicity. In summary, our findings provide evidence that DSPE-mPEG2k micelles could be considered potential carriers for future irinotecan delivery and their possible therapeutic application against colorectal cancer.